-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
How Much Of Ascletis Pharma Inc. (HKG:1672) Do Insiders Own?
How Much Of Ascletis Pharma Inc. (HKG:1672) Do Insiders Own?
Every investor in Ascletis Pharma Inc. (HKG:1672) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. Warren Buffett said that he likes "a business with enduring competitive advantages that is run by able and owner-oriented people." So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.
With a market capitalization of HK$4.0b, Ascletis Pharma is a small cap stock, so it might not be well known by many institutional investors. In the chart below, we can see that institutions are not really that prevalent on the share registry. Let's take a closer look to see what the different types of shareholders can tell us about Ascletis Pharma.
See our latest analysis for Ascletis Pharma
SEHK:1672 Ownership Breakdown July 13th 2022What Does The Institutional Ownership Tell Us About Ascletis Pharma?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
Since institutions own only a small portion of Ascletis Pharma, many may not have spent much time considering the stock. But it's clear that some have; and they liked it enough to buy in. So if the company itself can improve over time, we may well see more institutional buyers in the future. It is not uncommon to see a big share price rise if multiple institutional investors are trying to buy into a stock at the same time. So check out the historic earnings trajectory, below, but keep in mind it's the future that counts most.
SEHK:1672 Earnings and Revenue Growth July 13th 2022We note that hedge funds don't have a meaningful investment in Ascletis Pharma. With a 51% stake, CEO Jinzi Jason Wu is the largest shareholder. This implies that they possess majority interests and have significant control over the company. Investors usually consider it a good sign when the company leadership has such a significant stake, as this is widely perceived to increase the chance that the management will act in the best interests of the company. In comparison, the second and third largest shareholders hold about 9.7% and 6.0% of the stock.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.
Insider Ownership Of Ascletis Pharma
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
Our most recent data indicates that insiders own the majority of Ascletis Pharma Inc.. This means they can collectively make decisions for the company. So they have a HK$2.6b stake in this HK$4.0b business. Most would argue this is a positive, showing strong alignment with shareholders. You can click here to see if those insiders have been buying or selling.
General Public Ownership
The general public-- including retail investors -- own 21% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Private Company Ownership
We can see that Private Companies own 12%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too.
I like to dive deeper into how a company has performed in the past. You can access this interactive graph of past earnings, revenue and cash flow, for free.
If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Ascletis Pharma Inc.(HKG:1672)的每一位投资者都应该知道最强大的股东群体。内部人士通常持有大量较年轻、规模较小的公司,而大公司往往有机构作为股东。沃伦·巴菲特说,他喜欢“一家由有能力、以所有者为导向的人经营的、具有持久竞争优势的企业”。因此,看到一些内部人持股是件好事,因为这可能表明管理层是以所有者为导向的。
Ascletis Pharma的市值为40亿港元,是一只小盘股,因此可能并不为许多机构投资者所熟知。在下面的图表中,我们可以看到,机构在股票登记处并不是真的那么普遍。让我们仔细看看不同类型的股东能告诉我们关于Ascletis Pharma的什么。
查看我们对Ascletis Pharma的最新分析
联交所:1672所有权分类2022年7月13日关于Ascletis Pharma,机构所有权告诉了我们什么?
机构投资者通常将自己的回报与经常跟踪的指数的回报进行比较。因此,他们通常确实会考虑收购被纳入相关基准指数的较大公司。
由于机构只拥有Ascletis Pharma的一小部分股份,许多机构可能没有花太多时间考虑这只股票。但很明显,有些人已经这样做了;他们非常喜欢它,于是就买入了。因此,如果公司本身能够随着时间的推移而改善,我们很可能会在未来看到更多的机构买家。如果多个机构投资者试图同时买入一只股票,股价大幅上涨的情况并不少见。所以,看看下面的历史收益轨迹,但要记住,未来才是最重要的。
联交所:1672盈利及收入增长2022年7月13日我们注意到,对冲基金没有对Ascletis Pharma进行有意义的投资。持有51%股份的金姿CEO吴季刚是最大股东。这意味着他们拥有多数股权,并对公司拥有重大控制权。投资者通常认为,当公司领导层持有如此多的股份时,这是一个好兆头,因为人们普遍认为,这增加了管理层采取行动符合公司最佳利益的可能性。相比之下,第二大和第三大股东分别持有约9.7%和6.0%的股份。
研究机构持股是衡量和筛选股票预期表现的好方法。通过研究分析师的情绪,也可以达到同样的效果。分析师对该股的报道不多,但也不多。因此,它有获得更多报道的空间。
Ascletis Pharma的内部人所有权
不同国家对内部人的定义可能略有不同,但董事会成员总是算数的。公司管理层对董事会负责,董事会应代表股东的利益。值得注意的是,有时最高层管理人员本身也是董事会成员。
我通常认为内部人持股是一件好事。然而,在某些情况下,这会让其他股东更难让董事会对决策负责。
我们最新的数据显示,内部人士拥有Ascletis Pharma Inc.的大部分股份。这意味着他们可以集体为公司做出决定。因此,他们在这项价值40亿港元的业务中持有26亿港元的股份。大多数人会辩称,这是积极的,表明了与股东的强烈一致。你可以点击这里,看看这些内部人士是一直在买入还是卖出。
一般公有制
包括散户投资者在内的普通公众持有该公司21%的股份,因此不能轻易忽视。尽管这种规模的所有权可能不足以影响有利于他们的政策决定,但他们仍然可以对公司政策产生集体影响。
私营公司所有权
我们可以看到,私营公司拥有12%的已发行股份。私营公司可能是关联方。有时,内部人士通过持有一家私人公司来对上市公司感兴趣,而不是以个人身份。虽然很难得出任何大致的中风结论,但值得注意的是,这是一个值得进一步研究的领域。
接下来的步骤:
我发现看看到底是谁拥有一家公司是非常有趣的。但为了真正获得洞察力,我们还需要考虑其他信息。
我喜欢潜入更深的地方了解一家公司过去的表现。您可以访问此互动图过去的收益、收入和现金流,是免费的。
如果你更愿意了解分析师对未来增长的预测,请不要错过这一预期免费关于分析师预测的报告。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧